CClinicalTrials.gg
RecruitingNCT05648292SELFSEPUpdated Sep 6, 2023

The Relationships Between Personal Identity, Autobiographical Memory and Future Thinking in People With Multiple Sclerosis

An observational study in Multiple Sclerosis, Relapsing-Remitting and Healthy Controls, sponsored by Centre d'Investigation Clinique et Technologique 805. Recruiting at 1 site in France. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-09-06.

Sponsored by Centre d'Investigation Clinique et Technologique 805 · Observational

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 10 months ago, but the record still lists the study as recruiting.
  • Started Dec 2022; still recruiting 3 years 10 months later.
Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
90
Ages
18 Years to 55 Years
Sex
All
01

Study summary

Personal identity is composed of multiple facets of the self that are constructed and nourished through memories of past experiences (i.e., autobiographical memory) and the imagination of events that may occur in the future (i.e., future thinking) .

While our previous work has shown that people with relapsing-remitting multiple sclerosis (pwRRMS) have autobiographical memory and future thought disorders, their impact on personal identity has not yet been explored. Based on a cognitive and clinical neuropsychology approach, this research project aims to better understand the cognitive mechanisms involved in the relationship between identity, autobiographical memory and future thinking in pwRRMS. We will examine the extent to which pwRRMS manage to maintain and reshape their identity through life experiences, with a particular interest in the potential integration of the disease as a facet of their identity. In addition, we will explore the positive and/or negative consequences of disease-related identity changes on emotional well-being and quality of life, as well as their links with the duration and severity of the disease. Overall, this research project will contribute to identify new therapeutic levers that can be used for the development of adapted and personalized care.

02

Conditions studied

  • Multiple Sclerosis, Relapsing-Remitting
  • Healthy Controls
03

In context

Multiple Sclerosis

3,460 studies on the registry are indexed under Multiple Sclerosis; 661 are open to participants now.

This study's planned enrollment of 90 is close to the median of 100 across 1,016 observational studies indexed under Multiple Sclerosis.

Browse Multiple Sclerosis studies →

Lead sponsor

Centre d'Investigation Clinique et Technologique 805 is the lead sponsor of 74 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Primary care clinic

Eligibility criteria

For the clinical group:

Inclusion Criteria:

  • Diagnosis of relapsing-remitting MS according to the McDonald's revised diagnostic criteria
  • People aged between 18 and 55
  • French native speaker
  • Access to a computer or tablet, equipped with internet access, a camera and a microphone

Non-inclusion Criteria:

  • MS relapse in the month prior to the inclusion
  • Treatment with corticosteroids during the month preceding the inclusion
  • Form of MS other than the relapsing-remitting form
  • Neurological history (other than MS for patients), history or current presence of psychiatric disorders (e.g., depression, anxiety disorders, schizophrenia), substance abuse (e.g., alcohol, cannabis; past or present)
  • Other diagnosed chronic pathology(ies) (other than MS for patients)
  • Severe cognitive impairment
  • Persons mentioned in Articles L1121-6 to L1121-8 in the French law (minors, persons deprived of liberty, adults subject to protective measures)

For the control group:

Inclusion Criteria:

  • People aged between 18 and 55
  • Matched in age, gender and level in education
  • French native speaker
  • Access to a computer or tablet, equipped with internet access, a camera and a microphone

Non-inclusion Criteria:

  • Neurological history (other than MS for patients), history or current presence of psychiatric disorders (e.g., depression, anxiety disorders, schizophrenia), substance abuse (e.g., alcohol, cannabis; past or present)
  • Other diagnosed chronic pathology(ies) (other than MS for patients)
  • Severe cognitive impairment
  • Persons mentioned in Articles L1121-6 to L1121-8 in the French law (minors, persons deprived of liberty, adults subject to protective measures)
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
90 participants (estimated)
Target follow-up
15 Days
Patient registry
Yes

Groups and cohorts

  • Clinical group

    45 individuals with relapsing-remitting multiple sclerosis

    Behavioral: Neuropsychological tests and psychological questionnaires

  • Control group

    45 individuals with no chronic disease, matched in age, gender and level of education

    Behavioral: Neuropsychological tests and psychological questionnaires

Interventions

  • BehavioralNeuropsychological tests and psychological questionnaires

    * The clinical group will complete: * the BCcogSEP: a comprehensive neuropsychological examination * the IAM and I WILL BE tasks; experimental neuropsychological tasks to assess autobiographical memory, future thinking and personal identity * A series of questionnaires including the BRIEF COPE, the Connor Davidson Resilience Scale, the Satisfaction with Life Scale and the Hospital Anxiety and Depression Scale, which respectively assess coping strategies, resilience, life satisfaction and anxiety/depression * The control group will complete: * the IAM and I WILL BE tasks; experimental neuropsychological tasks to assess autobiographical memory, future thinking and personal identity * A series of questionnaires including the BRIEF COPE, the Connor Davidson Resilience Scale, the Satisfaction with Life Scale and the Hospital Anxiety and Depression Scale, which respectively assess coping strategies, resilience, life satisfaction and anxiety/depression

06

What researchers measure

Primary outcomes

  1. Relationships between personal identity, autobiographical memory and future thinking

    Scores obtained at the I AM and I WILL BE tasks assessing the access, qualitative properties of self-concepts, episodic richness and temporal organization of past and future events around self-concepts (between-group comparisons, pwRRMS versus control group)

    Time frame: 15 days

Secondary outcomes

  1. Relationships between personal identity, psychological functioning and clinical characteristics

    Correlations between IAM and I WILL BE scores and scores obtained at the different questionnaires (BRIEF COPE, Connor Davidson Resilience Scale, Satisfaction with Life Scale, Hospital Anxiety and Depression Scale) Correlations between IAM and I WILL BE scores and level of functional disability (Expanded Disability Status Scale) Correlations between IAM and I WILL BE scores and disease duration

    Time frame: 15 days

07

Study locations

1 of 1 sites recruiting
  • Hopital Raymond Poincaré Garches
    Garches, Hauts De Seine 92380, France
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05648292
Lead sponsor
Centre d'Investigation Clinique et Technologique 805
Collaborators
University Paris 8 Vincennes Saint Denis, ARSEP foundation
Responsible party
Alexandra Ernst (Associate Professor, Centre d'Investigation Clinique et Technologique 805) — Principal investigator
First posted
Dec 13, 2022
Start date
Dec 7, 2022
Primary completion
Dec 7, 2024 (estimated)
Completion
Jun 7, 2025 (estimated)
Last update
Sep 6, 2023

Study contacts

Alexandra Ernst, PhD
Contact
aernst@univ-paris8.fr
+33628496210
Alexandra ERNST, PhD
principal investigator · Laboratoire DysCo - Université Paris 8

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion